Clinical trials: Dyslipidemias
Dyslipidemias
Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study
To evaluate the percentage of Korean dyslipidemic subjects in the total group and each cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at starting doses of 10mg, 20mg and 40mg of atorvastatin…
- Trial name
- AT GOAL (NCT00540293)
- Testing
- Atorvastatin
- Where
- 20 sites in South Korea
- Volunteers
- 425 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Microbiome, Metabolic Syndrome
Dietary Fibers Effect on the Gut Microbiota Composition
The randomized double-blinded placebo-controlled multicenter study will be held in parallel groups. During 5 weeks the efficacy of different endpoints as a measure of response to the daily intake of dietary fibers (8 g of either…
- Conditions
- Microbiome, Metabolic Syndrome, Cardiovascular Risk Factor, Inflammation
- Trial name
- NCT04114513
- Testing
- Maltodextrin, Inulin, Pectin
- Where
- Russia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Atlas Biomed
Dyslipidemias
Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507
The purpose of this study is to determine the efficacy and safety of DWJ1506 and DWJ1507 in the patients with dyslipidemia.
- Trial name
- NCT04772443
- Testing
- DWJ1506, DWJ1507, DWC202011
- Volunteers
- 280 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension, Dyslipidemia
Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.
Noninferiority trial to assess efficacy of fixed-dose combination of valsartan + rosuvastatin versus their isolated components in treatment of hypertension and dyslipidemia.
- Trial name
- NCT02662894
- Testing
- Valsartan 160mg + Rosuvastatin 20mg, Valsartan 320mg + Rosuvastatin 20mg, Diovan® 160mg + Crestor® 20mg
- Sponsor
- EMS
Dyslipidemia
Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
The purpose of the study is to show the compliance rates of the patients to statin treatment and the reasons of non-compliance.
- Trial name
- NCT00673660
- Testing
- Patient Compliance
- Where
- 5 sites in Turkey (Türkiye)
- Volunteers
- 375 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cardiovascular, Dyslipidemia
Cardiovascular Events Based On Statin Initiation In The Elderly
The purpose of this study is to compare rates and risk of primary cardiovascular events among elderly patients newly initiating therapy with atorvastatin or simvastatin.
- Trial name
- NCT01304641
- Testing
- Atorvastatin Initiators, Simvastatin Initiators
- Volunteers
- 31,603 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST 2 (NCT00442325)
- Testing
- Atorvastatin (Lipitor)
- Where
- 32 sites in Greece, Hungary and 6 more
- Volunteers
- 595 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST (NCT00442845)
- Testing
- Atorvastatin (Lipitor)
- Where
- 121 sites in Cameroon, Canada and 3 more
- Volunteers
- 2,080 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dyslipidemias
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
The purpose of the study is to evaluate the effectiveness of atorvastatin in lowering cholesterol and getting these high risk patients to their goals of LDL <115 mg/dl across starting doses of 10 mg, 20 mg, or 40 mg with one step…
- Trial name
- NCT00644670
- Testing
- Atorvastatin
- Where
- 17 sites in Belgium
- Volunteers
- 232 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dyslipidemias
A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD)
A study of the long-term (1 year) effectiveness of atorvastatin to keep patients of high cardiovascular risk at the LDL cholesterol goal of <115 mg/dL
- Trial name
- NCT00644709
- Testing
- Atorvastatin
- Where
- 15 sites in Belgium
- Volunteers
- 196 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dyslipidemias
A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol
The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.
- Trial name
- LA ATGOAL (NCT00645151)
- Testing
- Atorvastatin
- Where
- 33 sites in Brazil, Chile and 6 more
- Volunteers
- 512 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dyslipidemias
Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand
The purpose of this study is to evaluate the efficacy of atorvastatin in lowering cholesterol on patients from Thailand with high cholesterol.
- Trial name
- NCT00647543
- Testing
- Atorvastatin
- Where
- 4 sites in Thailand
- Volunteers
- 242 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dyslipidemia
A Study to Evaluate the Efficacy of a Counselling and Advisory Care for Health (COACH) Program in Dyslipidemic Patients.
This study is a local PCO sponsored, interventional, non-drug study to evaluate the efficacy of a health tele-counselling program in reducing cardiovascular risk in dyslipidemic patients.
- Trial name
- DISSEMINATE (NCT00708370)
- Testing
- COACH
- Where
- 22 sites in Malaysia
- Volunteers
- 297 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Obesity, Smoking
Africa and Middle East Cardiovascular Epidemiological Study
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics…
- Conditions
- Obesity, Smoking, Dyslipidemia, Diabetes Mellitus
- Trial name
- ACE (NCT01243138)
- Where
- 73 sites in Algeria, Cameroon and 12 more
- Volunteers
- 4,386 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Familial Partial Lipodystrophy
Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
This is a single-center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3-LRx for reduction of fasting triglycerides in participants with familial partial lipodystrophy.
- Trial name
- NCT03514420
- Testing
- AKCEA-ANGPTL3-LRx
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Akcea Therapeutics
Dyslipidemia, Hypertension
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood…
- Trial name
- TOGETHER (NCT00412113)
- Testing
- Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 51 sites in United States
- Volunteers
- 245 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-348
- Trial name
- NCT04587206
- Testing
- CKD-348, CKD-828, D097, D337
- Where
- South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Dyslipidemia
Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population
The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
- Trial name
- CAPABLE (NCT00150384)
- Testing
- Amlodipine/Atorvastatin
- Where
- 106 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Dyslipidemia
Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia
To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.
- Trial name
- JEWEL I (NCT00330785)
- Testing
- Amlodipine/Atorvastatin
- Where
- 126 sites in Canada, United Kingdom
- Volunteers
- 1,250 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Dyslipidemia
Caduet in an Untreated Subject Population
The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these…
- Trial name
- CUSP (NCT00332761)
- Testing
- Caduet
- Where
- 34 sites in United States
- Volunteers
- 220 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.